427 related articles for article (PubMed ID: 16719816)
1. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG
Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
[TBL] [Abstract][Full Text] [Related]
2. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
Hashimoto K
Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
[TBL] [Abstract][Full Text] [Related]
3. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors.
Lindsley CW; Wolkenberg SE; Kinney GG
Curr Top Med Chem; 2006; 6(17):1883-96. PubMed ID: 17017963
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
Singer P; Dubroqua S; Yee BK
Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
[TBL] [Abstract][Full Text] [Related]
5. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
Kanuma K; Aoki T; Shimazaki Y
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
[TBL] [Abstract][Full Text] [Related]
6. The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice.
Chen HH; Stoker A; Markou A
Psychopharmacology (Berl); 2010 May; 209(4):343-50. PubMed ID: 20217053
[TBL] [Abstract][Full Text] [Related]
7. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H
Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471
[TBL] [Abstract][Full Text] [Related]
8. Glutamate-based therapeutic approaches: inhibitors of glycine transport.
Lechner SM
Curr Opin Pharmacol; 2006 Feb; 6(1):75-81. PubMed ID: 16376148
[TBL] [Abstract][Full Text] [Related]
9. Targeting glutamate synapses in schizophrenia.
Field JR; Walker AG; Conn PJ
Trends Mol Med; 2011 Dec; 17(12):689-98. PubMed ID: 21955406
[TBL] [Abstract][Full Text] [Related]
10. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
[TBL] [Abstract][Full Text] [Related]
11. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
Bridges TM; Williams R; Lindsley CW
Curr Opin Mol Ther; 2008 Dec; 10(6):591-601. PubMed ID: 19051137
[TBL] [Abstract][Full Text] [Related]
12. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex.
Lecourtier L; Homayoun H; Tamagnan G; Moghaddam B
Biol Psychiatry; 2007 Oct; 62(7):739-46. PubMed ID: 17511968
[TBL] [Abstract][Full Text] [Related]
13. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.
Menniti FS; Lindsley CW; Conn PJ; Pandit J; Zagouras P; Volkmann RA
Curr Top Med Chem; 2013; 13(1):26-54. PubMed ID: 23409764
[TBL] [Abstract][Full Text] [Related]
14. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia.
Matosin N; Newell KA
Neurosci Biobehav Rev; 2013 Mar; 37(3):256-68. PubMed ID: 23253944
[TBL] [Abstract][Full Text] [Related]
15. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
Shim SS; Hammonds MD; Kee BS
Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
[TBL] [Abstract][Full Text] [Related]
17. Modulation of striatal dopamine release by glycine transport inhibitors.
Javitt DC; Hashim A; Sershen H
Neuropsychopharmacology; 2005 Apr; 30(4):649-56. PubMed ID: 15688094
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine.
Clifton NE; Morisot N; Girardon S; Millan MJ; Loiseau F
Psychopharmacology (Berl); 2013 Feb; 225(3):579-94. PubMed ID: 22983144
[TBL] [Abstract][Full Text] [Related]
19. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
Yang CR; Svensson KA
Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
[TBL] [Abstract][Full Text] [Related]
20. The role of group I metabotropic glutamate receptors in schizophrenia.
Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
